Treatment of Multiple Sclerosis with a combination of laquinimod and teriflunomide

摘要

Methods of treatment for multiple sclerosis patients or patients with clinically isolated syndrome (CIS) include treating patients with laquinimood as an additional treatment, or combining an effective dose with a dose higher than the minimum streamline worm dose. A container and drug ingredient, including laquinimood, with an effective dose greater than that of the treatment one affected or indicated by pcdesOnly egg It also provides laquinimod as an additional treatment or in combination with effective doses of glycols above the minimum to treat patients with PCDDs or PCDFs. 1. When preparing the mixture for the treatment of patients with PCBs or single window patients, use aquiminod and tritium with an effective dose higher than the minimum. Claims 33: any claimed methods 1 to 31It is characterized by the fact that the subjects received leukemia treatment before starting treatment with laquinimud Claim 34: the method of claim 33, which is characterized by receiving stone treatment by an expert for at least 8 weeks, 10 weeks, 24 weeks, 28 weeks, 48 weeks or 52 weeks before starting treatment with laquinimod. Claims 36: Methods 1 to 35 of any one claim, characterized by regular management of laquinomoud and tritium for at least three days, more than 30 days, more than 42 days, eight weeks or more,Claim 41: a package having the following characteristics: a package containing (a) a first pharmaceutical ingredient, wherein a certain amount of liquid and an acceptable pharmaceutical transporter are contained; and (b) a certain amount of second pharmaceutical ingredient is contained. 1. Tritium is a kind of acceptable tritium and a means of transportation, in which the tritium content exceeds the minimum effective dose of tritium;(c) Instructions for the use of a combination of the first and second drugs in patients with multiple sclerosis or clinically isolated patients. Claim 42: the package of claim 41, which is characterized in that the first pharmaceutical ingredient, the second pharmaceutical ingredient or the first and second pharmaceutical ingredients are aerosol, inhalable, injectable, liquid, solid, capsule or compressed. Claim 58: any claimed packaging 41 to 57,characterized in that the amount of laquinimod in the first composition is less than 0.6 mg, or is between 0.1 and 40.0 mg, between 0.1 and 2.5 mg, between 0.25 and 2.0 mg, 0.5 to 1.2 mg, 0.25 mg, 0.3 mg, 0.5 mg, 0.6 mg, 1.0 mg, 1.2 mg, 1.5 mg or 2.0 mg. Claim 59: The package of any of claims 41 to 58, characterized in that the amount of teriflunomide is greater than 7 mg. Claim 60: The package of claim 59, characterized in that the amount of teriflunomide is 14 mg.